Next Article in Journal
Long Non-Coding RNAs in Haematological Malignancies
Next Article in Special Issue
Glycogen Synthase Kinase 3β Inhibition as a Therapeutic Approach in the Treatment of Endometrial Cancer
Previous Article in Journal
Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease
Previous Article in Special Issue
Pilot Study of CYP2B6 Genetic Variation to Explore the Contribution of Nitrosamine Activation to Lung Carcinogenesis
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2013, 14(8), 15376-15385;

The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer

Department of Obstetrics and Gynecology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
Comprehensive Cancer Center (CCC), Medical University of Vienna, A-1090 Vienna, Austria
Author to whom correspondence should be addressed.
Received: 21 June 2013 / Revised: 13 July 2013 / Accepted: 15 July 2013 / Published: 24 July 2013
(This article belongs to the Special Issue Molecular Research of Carcinogenesis)
Full-Text   |   PDF [773 KB, uploaded 19 June 2014]


The L10P single nucleotide polymorphism (SNP) is located in the signal sequence of the transforming growth factor β1 (TGFβ1) gene. The proline-encoding (Pro-) allele of this SNP has been associated with an increased breast cancer risk, which has been attributed to the elevated secretion of this TGFβ1 variant observed in vitro and in male subjects. Here we investigated the association of the L10P SNP with serum levels of TGFβ1 in female breast cancer patients and controls. We genotyped the L10P SNP in 276 breast cancer patients and 255 controls. Serum TGFβ1 concentrations were measured by enzyme-linked immunosorbent assay (ELISA) in a subset of the study population (n = 211). We found no evidence for an association of the L10P SNP with breast cancer risk (per-allele odds ratio: 0.91; 95% confidence interval: 0.71–1.16). However, patients with the Pro/Pro genotype exhibited a significantly younger age at breast cancer onset (55.2 ± 14.3 years) than Leu/Leu patients (60.6 ± 13.6 years; p = 0.04), which may reflect the ability of TGFβ to promote tumor progression. Mean TGFβ1 serum levels of Pro-allele carriers were 39.4 ± 7.4 ng/mL, whereas those of Leu/Leu subjects were 37.6 ± 6.0 ng/mL (p = 0.07). Thus, compared to a previous study of male subjects, we observed only a modest increase, if any, in TGFβ1 levels of female Pro-allele carriers. View Full-Text
Keywords: breast cancer; TGFβ1; rs1800470; L10P SNP; serum levels breast cancer; TGFβ1; rs1800470; L10P SNP; serum levels
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Taubenschuß, E.; Marton, E.; Mogg, M.; Frech, B.; Ehart, L.; Muin, D.; Schreiber, M. The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer. Int. J. Mol. Sci. 2013, 14, 15376-15385.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top